Oxxon Therapeutics is being acquired by Oxford BioMedica, which has been developing gene-based therapeutic vaccines for cancer and neurotherapy. The deal gives the U.K.'s Oxford BioMedica control of Hi-8 MEL, a cancer immunotherapy product that Oxford executives say is complementary to its own late-stage product, TroVax.
"The market opportunity for an effective melanoma vaccine is substantial and this is a cancer type where our immunotherapy, TroVax, cannot be developed because, unlike the vast majority of human tumors, melanomas do not have 5T4 on the surface of the tumor cells," says Oxford CEO Alan Kingsman. "This acquisition is part of the implementation of a plan for the development of our pipeline following finalization of a licensing deal for TroVax."
- see this press release for more
- read the report on the buyout from Science Business
Oxford BioMedica says licensing talks heating up. Report
BioMedica touts mid-stage Trovax trial data. Report